Prognostic factors and treatment outcomes have been identified in estrogen receptor (ER) low-positive early-stage breast cancer. This study evaluates outcomes in ER low-positive de novo metastatic breast cancer (dnMBC) patients.

We conducted a retrospective cohort study of adults with human epidermal receptor-2 negative dnMBC diagnosed from 2018 to 2021 in the National Cancer Database. We classified ER status as negative (< 1%), low-positive (1-10%), or positive (11-100%). We compared overall survival by ER status using Cox regression, adjusting for age, metastatic sites, race/ethnicity, comorbidities, insurance, and treatment receipt. We then analyzed the cohort with ER low-positive patients stratified by progesterone receptor (PR) status, defined as negative (< 1%) or positive (1-100%). Among ER low-positive patients, we evaluated survival by first-course treatment. We distinguished cytotoxic chemotherapy from cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) therapy based on the timing of endocrine therapy and chemotherapy.

Among 27,672 patients, 3% had ER low-positive dnMBC. ER low-positive/PR-positive patients had longer median (95% CI) survival [19.8 (14.8-24.8) months] compared to both ER low-positive/PR-negative [11.8 (10.6-13.5) months] and ER-negative [12.9 (12.5-13.6) months] patients. ER low-positive/PR-positive patients had decreased risk of death compared to ER-negative patients (hazard ratio = 0.84, 95% CI 0.71-1.00), while ER low-positive/PR-negative patients did not. ER low-positive dnMBC patients who received chemotherapy followed by endocrine therapy (± CDK4/6i) or endocrine therapy + CDK4/6i had improved or similar survival compared to patients who received chemotherapy alone.

PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.

Extramural venous invasion (EMVI) is a high-risk pathological feature in colorectal cancer, yet its role in guiding adjuvant chemotherapy in node-negative colon cancer remains uncertain. This study evaluates EMVI as a predictor of recurrence in patients undergoing colon cancer resection and investigates whether adjuvant chemotherapy affects recurrence in node-negative, EMVI-positive (N0/EMVI +) patients.

A retrospective cohort study was conducted on adults undergoing surgery for colon cancer at a single UK cancer centre between 2015 and 2022. Patients with rectal tumours or metastatic disease at presentation were excluded. Cox proportional hazards models were used to assess predictors of recurrence. Kaplan-Meier survival curves were generated to visualise recurrence-free survival (RFS) stratified by EMVI and chemotherapy status.

Among 675 patients, EMVI was present in 361 (53%). EMVI was independently associated with increased recurrence (HR: 1.80, 95% CI: 1.14-2.84, p=0.011). In the N0/EMVI+ subgroup (n=124), chemotherapy was not significantly associated with reduced recurrence: partial chemotherapy (HR: 1.36, 95% CI: 0.30-6.20, p=0.69), full chemotherapy (HR: 1.53, 95% CI: 0.46-5.12, p=0.49). Kaplan-Meier analysis revealed five-year RFS of 80.9% for no chemotherapy, 60.6% for partial chemotherapy, and 41.6% for full chemotherapy (p=0.69). Survival differences were not statistically significant.

EMVI is a predictor of recurrence in patients undergoing surgery for colon cancer. However, in node-negative patients with EMVI, chemotherapy was not significantly associated with improved recurrence-free survival. These findings highlight the need for larger, prospective studies to better define the role of EMVI in guiding adjuvant therapy in stage II colon cancer.

This study used contemporaneous networks and cross-lagged panel network (CLPN) to examine how the Simplified Sitting Badunjin (SSBDJ) intervention interacted with the fatigue, sleep disturbances, and quality of life (QoL) at different follow-up stages in advanced cancer patients.

This was a secondary analysis of a randomized controlled trial. Data were collected at baseline (T0), 4 weeks (T1), 8 weeks (T2), 12 weeks (T3) of the intervention, and 4 weeks (T4) after the intervention. A total of 3 constructs with 16 dimensions (fatigue severity, fatigue interference, sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, daytime dysfunction, physical discomfort, food related concerns, healthcare concerns, support, negative emotions, existential distress, sense of alienation, value of life) were included in the symptom network, which consists of contemporaneous and cross-lagged panel networks.

A total of 175 participants were included in the network analysis. Within the contemporaneous network, "Fatigue interference" emerged as the central symptom in both the intervention and control groups (intervention group: EI value = 1.249 (T1), 2.610 (T2); control group: EI value = 1.462 (T1), 1.950 (T2)). In the longitudinal network analysis, SSBDJ was strongly negatively associated with fatigue severity and interference at T0 → T1 (β = -0.497, -0.504) and T1 → T2 (β = -0.210, -0.256). Additionally, fatigue consistently served as a central node within the networks, demonstrating the highest out-expected influence across 12-week intervention period. The impact of fatigue (out-EI: r = 2.641) on sleep disturbances and quality of life tended to exert independent influence in the mid stage of intervention (T2 → T3). Furthermore, fatigue (out-predictability: r = 1.993) remained a dominant predictor of sleep disturbances and quality of life even after the intervention (T3 → T4).

This study enhances the understanding of the longitudinal relationships between the SSBDJ intervention, fatigue, sleep disturbances, and QoL among patients with advanced cancer. It could provide an important insight for designing precise symptom management strategies in mind-body exercise interventions among this population.

Colorectal cancer (CRC) is associated with a high mortality rate. Previous studies have shown that FOXQ1, MMP11, and CST1 play significant roles in various cancers, influencing the invasion and metastasis of tumors. However, their effects on colorectal cancer have not been fully investigated. The purpose of this research was to examine the expression of FOXQ1, MMP11, and CST1 in colorectal cancer (CRC) and to systematically as-sess how these factors relate to clinicopathological characteristics and patient survival outcomes.

This study retrospectively gathered paraffin-embedded samples from 110 CRC patients who underwent surgery between 2017 and 2018. Meanwhile, relevant data were obtained from public databases to analyze expression differences of FOXQ1, MMP11, and CST1 between tumor tissues and normal lung tissues. We examined the expression of FOXQ1, MMP11, and CST1 using immunohistochemistry. Furthermore, the associations among FOXQ1, MMP11, CST1, clinical-pathological parameters, and prognosis were systematically analyzed. Further verification of the in vitro results was conducted through qRT-PCR.

Expression of FOXQ1, MMP11, and CST1 in patients was high, with 83.6%, 67%, and 74.5%, respectively. Through rigorous quantitative analysis of clinical-pathological parameters, the study confirmed that these biomarkers have a close and clinically significant correlation with the progression of TNM staging and the occurrence of lymph node metastasis (p < 0.05). Bioinformatics analysis and qRT-PCR verification both indicated that the expression levels of FOXQ1, MMP11, and CST1 in colorectal cancer (CRC) tissues were significantly higher than those in adjacent non-cancerous tissues.

The research data indicate that the abnormal overexpression of FOXQ1, MMP11, and CST1 in CRC tissues is significantly correlated with poor clinical prognosis in patients. There may be a synergistic effect influencing the invasion and metastasis of tumor cells, positioning them as potential novel therapeutic targets for patients with CRC.

Our study aimed to analyze the molecular and clinical characteristics of angioimmunoblastic T-cell lymphoma (AITL), identify prognostic factors, and evaluate their implications for patient outcomes.

This retrospective study analyzed 33 patients diagnosed with AITL between 2012 and 2022 at our center. Clinical data, laboratory parameters, pathological findings, and treatment outcomes were evaluated. Survival analyses were performed using the Kaplan-Meier method, and prognostic factors were identified through univariate Cox regression analysis.

The median age was 64.1 ± 7.2 years, with male predominance (63.6%). Most patients presented with advanced disease (69.7% stage IV). Immunophenotypic analysis confirmed high expression of follicular helper T-cell markers, including PD-1 (96.9%), CXCL13 (83.3%), and BCL-6 (96.6%). EBV was detected in 72.7% of specimens by EBER-ISH and 90% by EBV-DNA PCR. Univariate analysis identified lower hemoglobin, decreased platelet counts, low albumin levels, and elevated β2-microglobulin as significant negative prognostic factors for progression-free survival (PFS). For overall survival (OS), low albumin levels (HR 0.8, 95% CI 0.69 - 0.92, p = 0.002) and elevated β2-microglobulin (HR 1.32, 95% CI 1.03 - 1.69, p = 0.029) were significant predictors of inferior outcomes. Interestingly, PD-1 positivity was associated with significantly better PFS (HR 0.03, 95% CI 0 - 0.52, p = 0.016).

This study highlights the aggressive nature of AITL and identifies several readily accessible laboratory parameters as important prognostic factors. The protective effect of PD-1 positivity on survival outcomes warrants further investigation. While CHOP/CHOPE remains the standard treatment, the addition of novel targeted therapies shows promise for improving patient outcomes in this challenging lymphoma subtype.

This study aimed to investigate the clinical features, coagulation, and risk factors of deep vein thrombosis (DVT) in patients with pelvic tumor and to construct a prediction model for postoperative DVT events.

Clinical data of 161 patients with pelvic tumors (preoperative DVT group n = 22, non-DVT group n = 139; postoperative DVT group n = 35, NDVT group n = 125; and one case of postoperative pulmonary thrombosis was excluded) were retrospectively analyzed. Age, BMI, disease type, FIGO stage, and coagulation parameters (prothrombin time, PT; activated partial thromboplastin time, APTT; fibrinogen, FIB; D-dimer, D-D; plasminogen activator inhibitor-1, PAI-1) were compared. The key variables were screened using principal component analysis. The prediction model for postoperative DVT was built through logistic regression, and its efficacy was tested using a ROC curve.

PT, D-D, and PAI-1 were significantly higher in the preoperative DVT group than in the non-DVT group (p < 0.001), and APTT was significantly shorter (p = 0.002). The postoperative DVT group was characterized by advanced age (p = 0.032), a higher proportion of ovarian and endometrial cancers, a greater percentage of advanced FIGO stages (p = 0.002), longer postoperative bedtime of more than 72 hours (p = 0.028), and higher levels of PT, FIB, D-D, and PAI-1 (p < 0.001). Principal component analysis showed age and D-D as the main contributing factors. The logistic regression model showed that age (OR = 1.02, p = 0.05), elevated D-D (OR = 1.02, p = 0.001), FIGO stages III and IV (OR = 3.60, p = 0.048), absence of thrombolytic prophylaxis in the postoperative period (OR = 2.85, p = 0.049), and the presence of adjuvant therapy in the postoperative period (OR = 1.02, p = 0.038) were independent risk factors for postoperative DVT, and the AUC of the model reached 0.865 (p < 0.001).

Age, preoperative DVT, D-D level, and tumor stage are independent predictors of postoperative DVT in pelvic tumors. The constructed prediction model has high clinical value.

Multiple myeloma is a plasma cell malignancy characterized by monoclonal immunoglobulin production. Daratumumab has improved therapeutic outcomes but can interfere with laboratory assessments.

A 73-year-old woman with IgG kappa multiple myeloma achieved remission after initial treatment, then relapsed and received DRD. A monoclonal IgG kappa spike was observed on follow-up SPEP and IFE.

Daratumumab, due to its IgG1 kappa structure, may mimic disease-related monoclonal proteins, potentially leading to false detection of residual disease and misclassification of complete response as very good partial response.

Recognizing such interference and ensuring strong clinician-biologist collaboration is essential for accurate response interpretation.

The aim of this study was to investigate the clinical and laboratory features of primary IgG-κ with κ free light chain plasma cell leukemia.

We retrospectively analyzed the clinical and laboratory features of a case of primary plasma cell leukemia of the IgG-κ with κ free light chain type and reviewed the literature on patients with primary plasma cell leukemia.

The patient's white blood cell count was 36.95 x 109/L, hemoglobin was 43 g/L, platelet count was 64 x 109/L. Push film review: the number of white blood cells was significantly increased, and a type of cell was seen, with medium cytosol, polarized nucleus, abundant cytoplasm, stained areas, and rounded inclusions, which accounted for 90% of the total number of white blood cells. IgG 89.8 g/L, IgA < 0.26 g/L, IgM < 0.26 g/L, complement C3 0.33 g/L, complement C4 0.09 g/L; blood β2 microglobulin > 24.4 mg/L, ferritin 429.72 ng/mL. Serum protein electrophoresis: M protein bands were found, and the M protein content was 71.84 g/L. Serum immunofixation electrophoresis: precipitating bands were found in the IgG lane, two precipitating bands were found in the κ lane, and the monoclonal immunoglobulin type was IgG-κ with κ free light chain type. Flow cytometry: plasma cells accounted for 69.61% of the total, and their immunophenotypes were CD28+, CD38+, CD138+, CD27+ partially, CD269+ in small amount, CD19-, CD20-, and intracellular immunoglobulin Kappa light chain restriction expression, suggesting primary plasma cell leukemia.

For primary plasma cell leukemia, we should pay attention to the changes in the abnormal morphology and number of plasma cells. With the help of bone marrow smear, flow cytometry and other tests, we can make a clear diagnosis as early as possible and actively carry out treatment at an early stage.

To analyze regional disparities in time-to-treatment initiation and initial therapeutic modalities adopted for malignant melanoma of the skin in Brazil between 2013 and 2023.

This is a cross-sectional study based on secondary data extracted from the Oncology Panel. Prevalence ratios and 95% confidence intervals for time-to-treatment initiation were estimated by treatment region and initial therapeutic modality using Poisson regression with robust variance.

A total of 23,145 records were analyzed. Surgery was the main initial therapeutic modality in all regions, with 89.0% of procedures performed within 30 days of diagnosis, especially in the Southern region (88.6%). In contrast, chemotherapy and radiotherapy were predominantly initiated after 60 days, with the highest percentages in the Northern region (56.1% and 77.4%).

Significant disparities in time-to-treatment initiation were observed between the Brazilian regions, regardless of therapeutic modality, except in the Midwest region regarding radiotherapy. The findings highlighted the need for actions to promote greater equity in access to cancer treatment, in accordance with Law No. 12732/2012, aiming to improve clinical outcomes for users.

To estimate prostate cancer survival according to socioeconomic and tumor characteristics in the municipality of Manizales, Colombia, during the 2008-2018 period, based on population-based data.

A population-based retrospective cohort study was conducted, including all incident cases of primary prostate cancer diagnosed in Manizales between 2008 and 2018, recorded in the Manizales Population-Based Cancer Registry. Overall survival was estimated using the Kaplan-Meier method, both for the total cohort and according to health insurance regimen, area of residence, socioeconomic position, age groups, histological type, essential Tumor-Node-Metastasis (TNM) classification, and risk according to Gleason score. The association between the variables of interest and survival was evaluated using Cox regression models.

The overall five-year survival was 76.5%. Significant differences in survival were identified according to the health insurance regimen, with the risk of death before five years being approximately twice as high in patients from the subsidized and non-affiliated regimen compared to those from the contributory, special, and exception regimen.

Prostate cancer survival in Manizales is lower than that reported in populations with higher levels of development. Significant gaps in survival persist according to the health insurance regimen, disadvantaging the most socioeconomically vulnerable population, possibly mediated by late diagnoses due to barriers in timely access to treatment.